Theranostics 2017; 7(8):2287-2288. doi:10.7150/thno.19286 This issue
1. Department of Cardiology, West China Hospital of Sichuan University, Chengdu, China;
2. Department of Cardiovascular Surgery, West China Hospital of Sichuan University, Chengdu, China.
* These two authors contributed equally to this work.
Commentary-article in Theranostics, Volume 6, 2068
This commentary highlights the findings by Tao et al. (Theranostics 2016; 6: 2068-2083) that targeting miR-433 may be a potential therapeutic strategy for myocardial fibrosis and subsequently discusses the obstacles and prospects associated with the application of therapeutic microRNAs in anti-fibrosis treatment.
Keywords: Cardiac fibrosis, microRNAs, Therapeutic targets.